Xiao Chen - Lansen Pharmaceutical Insider

Lansen Pharmaceutical Holdings Limited -- Hong Kong Stock  

HKD 1.31  0.01  0.76%

VP of Marketing and Bus. Devel.

Mr. Chen Xiao Yun is the Vice President of Marketing and Business Development of the Lansen Pharmaceutical Holdings Limited. Mr. Chen joined our Group in April 2013 and has over 23 years of experience in the pharmaceutical industry. Prior to joining our Group, Mr. Chen was the marketing director of Shanghai CP Guojian Pharmaceutical Co., Ltd
Age: 44  VP Since 2013      
86 574 8309 9777  http://www.lansen.com.cn
Chen obtained a bachelor of engineering degree majoring in pharmaceutical chemistry from China Pharmaceutical University in 1992 and a master?s degree in business administration from Fudan University in 1999.

Management Efficiency

The company has return on total asset (ROA) of 2.47 % which means that it generated profit of $2.47 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 20.06 % meaning that it generated $20.06 on every $100 dollars invested by stockholders.
The company has accumulated 95.62 M in total debt with debt to equity ratio (D/E) of 90.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Lansen Pharmaceutical Holdings Limited has Current Ratio of 1.06 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.

Entity Summary

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty prescription western pharmaceuticals for the treatment of rheumatic diseases in the People?s Republic of China and internationally. Lansen Pharmaceutical Holdings Limited (0503) is traded on Hong Kong Stock Exchange in Hong Kong. It is located in Ningbo, and employs 820 people.

Did you try this?

Run Performance Analysis Now

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
Hide  View All  NextLaunch Performance Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Lansen Pharmaceutical Holdings Limited to your portfolio

Top Management

Lansen Pharmaceutical Leadership Team
Guang Xu, Director
Stephen Hunt, Chairman
Xuezi Liu, Director
Xiao Chen, VP
Song Hou, CFO
Fang Tao, Director
Bang Liu, CEO
Jun Tang, Director
Jin Lee, Chairman
Hua Cheng, Director
Di Zhu, Director
Wenwei Huang, Executive
Zhen Wu, Chairman
Kee Chan, Director
Rong Zhou, SVP
Pui Yip, Director
Chi Mui, CFO
Fritz Horlacher, Director
Chiu Tang, Director
Wei Li, Director
Tsz Leung, Executive

Stock Performance

Lansen Pharmaceutical Performance Indicators